Medigene, bluebird expand TCR deal

Medigene AG (Xetra:MDG1) and bluebird bio Inc. (NASDAQ:BLUE) are adding two new targets and additional milestones to a 2016 deal to research and develop T cell receptor immunotherapies to treat cancer.

Medigene will receive an additional $8 million up front and is eligible for $250 million in milestones for each target, plus double-digit royalties...